SUCCESSES AND FAILURES OF CARDIOVASCULAR PREVENTION

cardiovascular disease, risk factors, preventive strategy, prevention paradoxes

1. Oganov RG. Failed expectations and paradoxes of preventive cardiology. Cardiovascular Therapy and Prevention 2009; 8 (7):4–10 (Оганов Р. Г. Несбывшиеся надежды и парадоксы профилактической кардиологии. Кардиоваскулярная терапия и профилактика 2009; 8 (7):4–10).

2. www.who.int/healthinfo/statistics/mortality/en

3. Ford ES, Ajani UA, Croft JB, et al. Expanding the Decrease in the U. S. Deaths from Coronary Dissease, 1980–2000. The New Engl J Med 2007; 256 (23): 2388–98.

4. Unal B, Critchley JA, Capewell S. Explaining the decline in coronary heart disease mortality in England and Wales, 1981–2000. Circulation 2004; 109: 1101–7.

5. Rose G. Sick individuals and sick populations. Internat J Epidemiology 1985; 14: 32–8.

6. Grodstein F, Stampher MJ, Manson JE, et al. Postmenopausal estrogen and progestin use and their risk of cardiovascular. N Engl J Med 1996; 335:453–61.

7. Bath P, Gray LJ. Association between hormone replacement therapy and subsequent stroke: a meta-analysis. BMJ 2005; 330:432.

8. Beral V, Banks E, Reeves G. Evidence from randomized trials on long-term effects of hormone replacement therapy. Lancet 2002; 360:942–4.

9. Peverill R. Hormone therapy and venous thromboembolism. Best Pract Res Clin Endocrinol Metab 2002; 17:149–64.

10. Gratsiansky NA. Although evidences for the use of hormone replacement therapy with estrogen are existed, whereas CHD prevention is not among them. Cardiology 2000;6: 23. Russian (Грацианский Н. А. Если и существуют показания для применения гормональной заместительной терапии эстрогенами, то предупреждение КБС в их число пока не входит. Кардиология 2000; 6: 23).

11. Lavie CJ, Milani RV, Ventura HO. Obesity and cardiovascular disease: risk factor, paradox, and impact of weight loss. JACC 2009; 53:1925–32.

12. Ades PA, Savage PD. The obesity paradox: perception vs knowledge. Mayo Clin Proc 2010; 85:112–4.

13. Badheka AO, Rathold A, Kizibash, et al. Influence of obesity on outcomes in atrial fibrillation: yet another obesity paradox. Am J Med 2010; 123:646–51.

14. Continho T, Goel K, Correa de Sa D, et al. Central obesity and survival in subjects with CAD: a systematic review of the literature and collaborative analysis utilizing individual subjects data. JACC 2011; 57:1877–86.

15. Bays HE. Adiposopathy is “Sick Fat” a Cardiovascular Disease? JACC 2011; 57:2461–73.

16. Kallikazaros I. E. Obesity:”Less is more”. Hellenic J Cardiol 2013; 54:333–6.

17. Barbash GI, Reiner J, White HD, et al. Evaluation of paradoxic beneficial effects of smoking in patients receiving thrombolytic therapy for acute myocardial infarction: mechanism of the “smoking paradox” from the GUSTO-I trial with angiographic insights. JACC 1995; 26:1222–9.

18. Hasadi D, Lerman A, Rihal ES, et al. Smoking status and outcome after primary angioplasty for acute myocardial infarction. Am Heart J 1999; 137:612–20.

19. Ovbiagele B, Saver JL. The smoking-thrombolysis paradox and acute ischemic stroke. Neurology 2005; 65:293–5.

20. Suskin N, Pipe A, Prior P. Smokers paradox or not in heart failure, just quit. Eur Heart J 2008; 29:1932–3.

21. Elwood PC, Pickeriog JE, Givens DI, Gollacher JE. The consumption of milk and dairy foods and the incidence of vascular disease and diabetes: an overview of the evidence. Lipids 2010; 45:925–39.

22. Rong Ying, Chen Li, Zhu Tingting, et al. Egg consumption and risk of coronary heart disease and stroke: dose response meta-analysis of prospective cohort studies. BMJ 2013: e 8539.